Search

Your search keyword '"Sarosdy, Michael"' showing total 262 results
Start Over Author "Sarosdy, Michael"
262 results on '"Sarosdy, Michael"'

2. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer

Author

Grossman, H. Barton, Natale, Ronald B., Tangen, Catherine M., Speights, V.O., Vogelzang, Nicholas J., Trump, Donald L., White, Ralph W. deVere, Sarosdy, Michael F., Wood, David P., Jr., Raghavan, Derek, and Crawford, E. David

Subjects
Bladder cancer -- Care and treatment, Bladder cancer -- Prognosis
Abstract

Giving patients with bladder cancer chemotherapy followed by surgery may improve their outcome, according to a study of 307 patients. Patients who received this combined treatment survived an average of six years whereas those treated with surgery only survived an average of four years. The chemotherapy included methotrexate, vinblastine, doxorubicin, and cisplatin.

Published
2003

4. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenopathy in men with node-positive prostate cancer

Author

Messing, Edward M., Manola, Judith, Sarosdy, Michael, Wilding, George, Crawford, E. David, and Trump, Donald

Subjects
Prostate cancer -- Care and treatment, Hormone therapy -- Evaluation
Abstract

Therapy to suppress male sex hormones appears to be beneficial for men with prostate cancer who have had their prostate removed. Sex hormones can often stimulate cancers. Researchers randomly assigned 98 men with prostate cancer who had their prostate removed to have anti-androgen therapy or no further treatment. At the last follow-up, 77% of the men who received anti-androgen therapy were alive and well compared to 18% of the men who did not. Men who received anti-androgen therapy were also less likely to have a relapse.

Published
1999

14. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder

Author

Lamm, Donald L., Blumenstein, Brent A., Crawford, E. David, Montie, James E., Scardino, Peter, Grossman, H. Barton, Stanisic, Thomas H., Smith, Joseph A., Jr., Sullivan, Jerry, Sarosdy, Michael F., Crissman, John D., and Coltman, Charles A.

Subjects
Bladder cancer -- Drug therapy, Doxorubicin -- Evaluation, BCG -- Evaluation, Bladder cancer -- Development and progression
Abstract

Immunotherapy using bacille Calmette-Guerin (BCG) is an approved treatment for carcinoma in situ (early stage cancer) of the bladder, and its superiority over surgery alone and as a preventive agent has been shown in several randomized, controlled trials. However, randomized studies have not been carried out to compare the effectiveness of BCG with that of chemotherapeutic drugs such as doxorubicin (known to prevent tumor recurrence). A study was conducted of 262 patients with either rapidly recurrent (131 patients) or in situ transitional-cell carcinoma of the bladder. Patients were treated prophylactically if they were tumor-free, and therapeutically if they had carcinoma in situ. They were randomly assigned to receive either BCG or doxorubicin in the bladder, with the option of changing to the other treatment if recurrence took place. Patients were followed-up for a median time of 65 months, with treatment effectiveness evaluated by biopsy and urinalysis. Treatment with BCG was associated with a greater number of adverse effects, few of which were severe; the number of at least moderate effects was similar in the two groups. BCG treatment led to a greater proportion (70 percent) of complete responses (complete disappearance of disease) than doxorubicin (34 percent) in patients with carcinoma in situ, and a complete response was seen sooner after treatment started with BCG. Recurrences, when seen, took place after 5.1 months (median value) in doxorubicin patients and after 39 months in BCG patients. Those who received BCG had a probability, after five years, of disease-free survival of 45 percent, compared with 18 percent after doxorubicin. Patients with tumors without carcinoma in situ had a probability of disease-survival at five years of 37 percent with BCG and of 17 percent with doxorubicin, and a time to treatment failure of 10.4 months and 22.5 months, respectively. These findings, which include results from 46 medical institutions, indicate that BCG is no more toxic than standard chemotherapy and that it can be administered safely and effectively. (Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1991

18. DETECTION OF RECURRENT BLADDER CANCER USING A NEW ONE-STEP TEST FOR BLADDER TUMOR ANTIGEN

Author

Sarosdy, Michael F., Hudson, M'liss A., Ellis, William J., Soloway, Mark S., deVere White, Ralph W., Sheinfeld, Joel, Jarowenko, Mark V., Schellhammer, Paul F., Messing, Edward M., Schervish, Ed W., Patel, Jay V., Chodak, Gerald W., Lamm, Donald L., Johnson, Robert D., Henderson, Mary, Adams, George, Blumenstein, Brent A., Thoelke, Kent R., Brunelle, Sharon L., Pfalzgraf, Randy D., and Murchison, Heather A.

Published
1997

20. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma: analysis of time to progression

Author

Schellhammer, Paul F., Sharifi, Roohollah, Block, Norman L., Soloway, Mark S., Venner, Peter M., Patterson, A. Lynn, Sarosdy, Michael F., Vogelzang, Nicholas J., Chen, Yusong, and Kolvenbag, Geert J.C.M.

Subjects
Prostate cancer, Flutamide -- Health aspects, Gonadotropin releasing hormone -- Health aspects, Antiandrogens -- Health aspects, Health
Published
1996

34. Making the case for brachytherapy

Author

Sarosdy, Michael F.

Subjects
Care and treatment, Cancer treatment, Brachytherapy, Nuclear radiation, Prostate cancer -- Care and treatment, Cancer -- Care and treatment, Radioisotope brachytherapy
Abstract

Does brachytherapy deserve its reputation as the safest and least expensive of the three main treatments for prostate cancer (radical prostatectomy [RP] and external beam radiation therapy [EBRT])? Dr. Sarosdy: [...]

Published
2012

37. Genetic pattern of prostate cancer progression

Author

Saric, Tomo, primary, Brkanac, Zoran, additional, Troyer, Dean A., additional, Padalecki, Susan S., additional, Sarosdy, Michael, additional, Williams, Kenneth, additional, Abadesco, Leo, additional, Leach, Robin J., additional, and O'Connell, Peter, additional

Published
1999
Full Text
View/download PDF

39. MAINTENANCE BCG IMMUNOTHERAPY

Author

Lamm, Donald L, primary, Crissman, John D, additional, Montie, James E, additional, Gottesman, James B, additional, Lowe, Bruce A, additional, Sarosdy, Michael F, additional, Bohl, Robert D, additional, Grossman, Herbert B, additional, Beck, Thomas M, additional, Leimert, Joseph T, additional, Crawford, Edward D, additional, Kosecka, Urszula, additional, and Wittes, Robert C., additional

Published
1999
Full Text
View/download PDF

40. Comparison of goserelin and leuprolide in combined androgen blockade therapy

Author

Sarosdy, Michael F, primary, Schellhammer, Paul F, additional, Sharifi, Roohollah, additional, Block, Norman L, additional, Soloway, Mark S, additional, Venner, Peter M, additional, Patterson, A.Lynn, additional, Vogelzang, Nicholas J, additional, Chodak, Gerald W, additional, Klein, Eric A, additional, Jones Schellenger, Julie, additional, and Kolvenbag, Geert J.C.M, additional

Published
1998
Full Text
View/download PDF

43. Nical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: Final report of a double-blind, randomized, multicenter trial

Author

Schellhammer, Paul F., primary, Sharifi, Roohollah, additional, Block, Norman L., additional, Soloway, Mark S., additional, Venner, Peter M., additional, Lynn Patterson, A., additional, Sarosdy, Michael F., additional, Vogelzang, Nicholas J., additional, Schellenger, Julie Jones, additional, and Kolvenbag, Geert J.C.M., additional

Published
1997
Full Text
View/download PDF

44. Improved detection of recurrent bladder cancer using the bard bta stat test

Author

Sarosdy, Michael F., primary, Hudson, M'Liss A., additional, Ellis, William J., additional, Soloway, Mark S., additional, White, Ralph deVere, additional, Sheinfeld, Joel, additional, Jarowenko, Mark V., additional, Schellhammer, Paul F., additional, Schervish, Ed W., additional, Patel, Jay V., additional, Chodak, Gerald W., additional, Lamm, Donald L., additional, Johnson, Robert D., additional, Henderson, Mary, additional, Adams, George, additional, Blumenstein, Brent A., additional, Thoelke, Kent R., additional, Pfalzgraf, Randy D., additional, Murchison, Heather A., additional, and Brunelle, Sharon L., additional

Published
1997
Full Text
View/download PDF

49. In Reply

Author

Sharkey, Francis E., primary and Sarosdy, Michael F., additional

Published
1997
Full Text
View/download PDF

50. Urinary Nuclear Matrix Protein as a Marker for Transitional Cell Carcinoma of the Urinary Tract

Author

Carpinito, Gennaro A., primary, Stadler, Walter M., additional, Briggman, Joseph V., additional, Chodak, Gerald W., additional, Church, Paul A., additional, Lamm, Donald L., additional, Lange, Paul H., additional, Messing, Edward M., additional, Pasciak, Robert M., additional, Reservitz, George B., additional, Ross, Robert N., additional, Rukstalis, Daniel B., additional, Sarosdy, Michael F., additional, Soloway, Mark S., additional, Thiel, Robert P., additional, Vogelzang, Nicholas, additional, and Hayden, Cheryl L., additional

Published
1996
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results